<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Am J Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Am J Case Rep</journal-id>
      <journal-id journal-id-type="publisher-id">amjcaserep</journal-id>
      <journal-title-group>
        <journal-title>The American Journal of Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1941-5923</issn>
      <publisher>
        <publisher-name>International Scientific Literature, Inc.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27262587</article-id>
      <article-id pub-id-type="pmc">4917070</article-id>
      <article-id pub-id-type="doi">10.12659/AJCR.898500</article-id>
      <article-id pub-id-type="publisher-id">898500</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chinnadurai</surname>
            <given-names>Thiru</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-amjcaserep-17-379">
            <sup>A</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn2-amjcaserep-17-379">
            <sup>B</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn3-amjcaserep-17-379">
            <sup>C</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-379">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-17-379">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-17-379">
            <sup>F</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn7-amjcaserep-17-379">
            <sup>G</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-379">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c1-amjcaserep-17-379"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shrestha</surname>
            <given-names>Srijan</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn2-amjcaserep-17-379">
            <sup>B</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-379">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-17-379">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-17-379">
            <sup>F</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn7-amjcaserep-17-379">
            <sup>G</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-379">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ayinla</surname>
            <given-names>Raji</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn1-amjcaserep-17-379">
            <sup>A</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn3-amjcaserep-17-379">
            <sup>C</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-17-379">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-17-379">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-17-379">
            <sup>F</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn7-amjcaserep-17-379">
            <sup>G</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-17-379">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="af2-amjcaserep-17-379">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="af1-amjcaserep-17-379"><label>1</label>Department of Medicine, Harlem Hospital Center in affiliation with Columbia University College of Physician and Surgeons, New York, NY, U.S.A.</aff>
      <aff id="af2-amjcaserep-17-379"><label>2</label>Division of Pulmonary Medicine, Department of Medicine, Harlem Hospital Center in affiliation with Columbia University College of Physician and Surgeons, New York, NY, U.S.A.</aff>
      <author-notes>
        <fn>
          <p>Authors&#x2019; Contribution:</p>
        </fn>
        <fn id="fn1-amjcaserep-17-379">
          <label>A</label>
          <p>Study Design</p>
        </fn>
        <fn id="fn2-amjcaserep-17-379">
          <label>B</label>
          <p>Data Collection</p>
        </fn>
        <fn id="fn3-amjcaserep-17-379">
          <label>C</label>
          <p>Statistical Analysis</p>
        </fn>
        <fn id="fn4-amjcaserep-17-379">
          <label>D</label>
          <p>Data Interpretation</p>
        </fn>
        <fn id="fn5-amjcaserep-17-379">
          <label>E</label>
          <p>Manuscript Preparation</p>
        </fn>
        <fn id="fn6-amjcaserep-17-379">
          <label>F</label>
          <p>Literature Search</p>
        </fn>
        <fn id="fn7-amjcaserep-17-379">
          <label>G</label>
          <p>Funds Collection</p>
        </fn>
        <fn id="fn8-amjcaserep-17-379">
          <p><bold>Conflict of interest:</bold> None declared</p>
        </fn>
        <corresp id="c1-amjcaserep-17-379">Corresponding Author: Thiru Chinnadurai, e-mail: <email>thiru.chinnadurai@nychhc.org</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>05</day>
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <volume>17</volume>
      <fpage>379</fpage>
      <lpage>383</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Am J Case Rep, 2016</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license>
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</license-p>
        </license>
      </permissions>
      <abstract>
        <p>
          <bold>Patient: Male, 29</bold>
        </p>
        <p>
          <bold>Final Diagnosis: Inhalation fever induced by synthetic cannabinoid</bold>
        </p>
        <p>
          <bold>Symptoms: Agitation &#x2022; smoked synthetic cannabinoid</bold>
        </p>
        <p>
          <bold>Medication: Ringer&#x2019;s lactate solution &#x2022; Ceftriaxone &#x2022; Azithromycin&#x2022; Magnesium sulfate &#x2022; Potassium Phosphate &#x2022; Levofloxacin &#x2022; Risperidone</bold>
        </p>
        <p>
          <bold>Clinical Procedure: Chest radiograph &#x2022; CBC &#x2022; urine toxicology</bold>
        </p>
        <p>
          <bold>Specialty: Pulmonology</bold>
        </p>
        <sec>
          <title>Objective:</title>
          <p>
            <bold>Unusual clinical course</bold>
          </p>
        </sec>
        <sec>
          <title>Background:</title>
          <p>This case report describes inhalation fever as an uncommon pulmonary adverse effect of synthetic cannabinoids.</p>
        </sec>
        <sec>
          <title>Case Report:</title>
          <p>A 29-year-old man was brought in for severe agitation after smoking K2, a synthetic cannabinoid. He required multiple doses of lorazepam and haloperidol for sedation. His vital signs were notable for a mild fever and tachycardia. Otherwise, the rest of his exam was unremarkable. The laboratory test was significant for leucocytosis and diffuse reticular-nodular and interstitial infiltrates on chest radiograph. Urine drug toxicology was negative. Interestingly, his symptoms and pulmonary infiltrates on the chest radiograph resolved spontaneously after 24 hours of observation.</p>
        </sec>
        <sec>
          <title>Conclusions:</title>
          <p>This patient developed transient pulmonary infiltrates and fever following the synthetic cannabinoid inhalation, as seen in self-limiting inhalation fever. Inhalation fever as a consequence of synthetic cannabinoid has not been described previously and there is a need for further research in this field.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>MeSH Keywords</title>
        <kwd>Cannabis</kwd>
        <kwd>Pneumonia</kwd>
        <kwd>Smoke Inhalation Injury</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Synthetic cannabinoids (SC) consumption has been increasing steadily [<xref rid="b1-amjcaserep-17-379" ref-type="bibr">1</xref>&#x2013;<xref rid="b4-amjcaserep-17-379" ref-type="bibr">4</xref>] due to its appeal to users as an alternative to natural marijuana and its wide availability commercially [<xref rid="b2-amjcaserep-17-379" ref-type="bibr">2</xref>,<xref rid="b3-amjcaserep-17-379" ref-type="bibr">3</xref>]. The substance is usually sold as herbal blends, potpourri, and incense [<xref rid="b2-amjcaserep-17-379" ref-type="bibr">2</xref>,<xref rid="b3-amjcaserep-17-379" ref-type="bibr">3</xref>,<xref rid="b5-amjcaserep-17-379" ref-type="bibr">5</xref>]. It is smoked or ingested for simulated effects of the endocannabinoid system [<xref rid="b5-amjcaserep-17-379" ref-type="bibr">5</xref>,<xref rid="b6-amjcaserep-17-379" ref-type="bibr">6</xref>].</p>
      <p>An online global survey found a higher relative risk of synthetic cannabinoids compared to cannabis users among 22 289 respondents using emergency medical services [<xref rid="b7-amjcaserep-17-379" ref-type="bibr">7</xref>]. The American Association of Poison Control Centers reported 1900 synthetic cannabinoid exposure calls from January 1 to April 22 2015, four times the rate of calls received in 2014 [<xref rid="b6-amjcaserep-17-379" ref-type="bibr">6</xref>].</p>
      <p>Dyspnea is common among SC users [<xref rid="b8-amjcaserep-17-379" ref-type="bibr">8</xref>]. On the other hand, pulmonary sequelae have been reported rarely, as evidenced by a case series of 4 patients with organizing pneumonia, a case report of severe lung injury after chronic SC inhalation, and a case report of diffuse alveolar hemorrhage after SC use [<xref rid="b9-amjcaserep-17-379" ref-type="bibr">9</xref>&#x2013;<xref rid="b11-amjcaserep-17-379" ref-type="bibr">11</xref>].</p>
      <p>We present a case of a young man with fever who developed transient pulmonary infiltrates after inhalation of K2, a synthetic cannabinoid.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 29-year-old man, previously healthy, was brought in to the emergency department (ED) for severe agitation after smoking K2, a synthetic cannabinoid. He was asymptomatic of myalgia, upper respiratory tract symptoms, pleuritic chest pain, and dyspnea. He admitted to smoking K2 and was found by the ED team to be in possession of K2. He had a past history of schizoaffective disorder and was not on any treatment. He denied prior history of illicit drug use. He had no prior hospital admission to our center for substance abuse. There was no other medical history.</p>
      <p>He required multiple doses of lorazepam and haloperidol to be sedated. On examination, he was found to be drowsy but arousable. His vital signs were a mild fever of 100.2&#xB0;F (37.9&#xB0;C), blood pressure 110/50 mmHg, tachycardia of 109/min, respiratory rate of 18/min, and oxygen saturation of 95%. The chest examination showed good air entry on both lung fields, no crackles, no wheeze, and no rhonchi on auscultation. A cardiovascular exam noted that JVP was not elevated, S1 and S2 were heard, no additional heart sounds, no murmurs, no rubs, rate and rhythm were regular. Otherwise, the rest of examination was unremarkable. The laboratory test (<xref ref-type="table" rid="t1-amjcaserep-17-379">Table 1</xref>) was significant for leukocytosis (18.5) with predominant neutrophilia (83.4%). Urine drug toxicology (<xref ref-type="table" rid="t1-amjcaserep-17-379">Table 1</xref>) was negative for cannabinoids, phencyclidine, cocaine, benzodiazepine, methadone, opiates, and barbiturates. The chest radiograph (<xref ref-type="fig" rid="f1-amjcaserep-17-379">Figure 1</xref>) on admission noted diffuse reticular-nodular and interstitial infiltrates. Two blood culture samples were taken on admission, returned later as no growth after 5 days of incubation.</p>
      <p>The patient was hydrated with Ringer&#x2019;s lactate solution and given stat doses of Ceftriaxone 1 g intravenously, Azithromycin 500 mg intravenously, magnesium sulfate 2 g intravenous for hypomagnesemia, potassium phosphate 22 mEq intravenous for hypophosphatemia, Famotidine 40 mg oral daily for gastrointestinal prophylaxis, and heparin 5000 units subcutaneously twice daily for venous thromboembolism prophylaxis.</p>
      <p>At 24 hours after admission, his mentation improved and temperature returned to within normal limits. A repeat chest radiograph 24 hours after admission (<xref ref-type="fig" rid="f2-amjcaserep-17-379">Figures 2</xref>, <xref ref-type="fig" rid="f3-amjcaserep-17-379">3</xref>) noted resolution of the pulmonary infiltrates. However, he refused repeat blood investigations to assess for improvement of abnormal blood values from admission.</p>
      <p>The patient was concluded to have a diagnosis of inhalation fever caused by synthetic cannabinoid. He was discharged in stable condition from the hospital with advice to abstain from synthetic cannabinoids and he was given a course of oral levofloxacin 750 mg daily for 7 days for empirical treatment of pneumonia and Risperidone 1 mg oral twice daily for 2 weeks for schizoaffective disorder. Although an outpatient clinic appointment was scheduled for the patient, he was lost to follow-up and the long-term outcome is unknown.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>There are more than 50 specific types of SC reported in the United States [<xref rid="b12-amjcaserep-17-379" ref-type="bibr">12</xref>&#x2013;<xref rid="b14-amjcaserep-17-379" ref-type="bibr">14</xref>]. SC markedly differs from natural marijuana in terms of metabolism, receptor affinity, and clinical effects [<xref rid="b13-amjcaserep-17-379" ref-type="bibr">13</xref>&#x2013;<xref rid="b15-amjcaserep-17-379" ref-type="bibr">15</xref>]. Frequently encountered SC molecular structures include JWH-018, AM-2201, AB-001, AM-1220, and JWH-015 [<xref rid="b13-amjcaserep-17-379" ref-type="bibr">13</xref>].</p>
      <p>Both synthetic cannabinoids and delta-9 tetrahydrocannabinol act on the endocannabinoid receptors, the cannabinoid (CB) receptor-1 that is found in the central nervous system and CB-2 receptors in the immune system [<xref rid="b13-amjcaserep-17-379" ref-type="bibr">13</xref>,<xref rid="b14-amjcaserep-17-379" ref-type="bibr">14</xref>]. A study by Bronova et al. showed CB-1 receptor-mediated signalling of pulmonary fibrogenesis in radiation-exposed mice [<xref rid="b16-amjcaserep-17-379" ref-type="bibr">16</xref>]. Transient receptor potential vanilloid 4 (TRPV-4) that can be activated by endogenous N-acylamine cannabinoids and fatty acid-derived products related to anandamide during lung injury (chlorine gas or intratracheal hydrochloric acid). TRPV-4 activation can increase lung capillary permeability and trigger alveolar edema and has inflammatory effects. TRPV-4 inhibitors were shown to have anti-inflammatory effect [<xref rid="b17-amjcaserep-17-379" ref-type="bibr">17</xref>,<xref rid="b18-amjcaserep-17-379" ref-type="bibr">18</xref>].</p>
      <p>Our patient developed inhalation fever caused by K2, given the transient pulmonary infiltrates and fever following SC inhalation [<xref rid="b19-amjcaserep-17-379" ref-type="bibr">19</xref>&#x2013;<xref rid="b22-amjcaserep-17-379" ref-type="bibr">22</xref>]. Inhalation fever is defined by as a non-allergic, noninfectious, flu-like syndrome, commonly occurring after acute inhalation of organic dusts, metal and plastic fumes [<xref rid="b20-amjcaserep-17-379" ref-type="bibr">20</xref>&#x2013;<xref rid="b22-amjcaserep-17-379" ref-type="bibr">22</xref>]. However, this patient did not experience symptoms of malaise, nausea, myalgia, headache, cough, or dyspnea, which are symptoms associated with inhalation fever [<xref rid="b21-amjcaserep-17-379" ref-type="bibr">21</xref>,<xref rid="b22-amjcaserep-17-379" ref-type="bibr">22</xref>]. Leucocytosis is a feature seen in inhalation fever [<xref rid="b21-amjcaserep-17-379" ref-type="bibr">21</xref>,<xref rid="b22-amjcaserep-17-379" ref-type="bibr">22</xref>]. Inhalation fever is associated with a transient, self -limiting course and it is treated with supportive care and avoidance of the causative factor [<xref rid="b22-amjcaserep-17-379" ref-type="bibr">22</xref>].</p>
      <p>Acute hypersensitivity pneumonitis can present in a similar manner, as they occur rapidly within several hours of exposure to an antigen that triggers an immune response [<xref rid="b23-amjcaserep-17-379" ref-type="bibr">23</xref>,<xref rid="b24-amjcaserep-17-379" ref-type="bibr">24</xref>]. It can be associated with mild or absent symptoms and can resolve after hours or days [<xref rid="b23-amjcaserep-17-379" ref-type="bibr">23</xref>]. Chest radiographic findings have been reported to be normal or numerous poorly defined small (less than 5-mm) opacities throughout both lungs, occasionally with sparing of the apices and bases [<xref rid="b24-amjcaserep-17-379" ref-type="bibr">24</xref>]. Acute hypersensitivity pneumonitis can be non-progressive and intermittent, with spontaneous improvement after antigen avoidance [<xref rid="b23-amjcaserep-17-379" ref-type="bibr">23</xref>].</p>
      <p>Inhalation of particles can deposit along the respiratory tract from the upper airways to the tracheobronchial tree and alveolus depending on the particulate size and solubility in water [<xref rid="b25-amjcaserep-17-379" ref-type="bibr">25</xref>]. Acute chemical pneumonitis may thus present as an inflammatory reaction to the particulate in the form of bronchitis, bronchiolitis, pulmonary edema, diffuse alveolar hemorrhage, and acute respiratory distress syndrome [<xref rid="b25-amjcaserep-17-379" ref-type="bibr">25</xref>]. Chemical pneumonitis can be an effect of the inhaled drug itself or contaminants present in the inhaled substance [<xref rid="b26-amjcaserep-17-379" ref-type="bibr">26</xref>]. Resolution of the symptoms can occur with withdrawal of the offending substance [<xref rid="b26-amjcaserep-17-379" ref-type="bibr">26</xref>].</p>
      <p>Lastly, we had considered a diagnosis of bacterial pneumonia in this patient, as he had presented with low-grade fever, tachycardia, leukocytosis, and chest radiographic evidence of pulmonary infiltrates on admission. He was given a course of oral levofloxacin as empiric treatment. However, infection is less likely, as evidenced by the repeat chest radiograph at 24 hours after admission demonstrating resolution of the infiltrates and negative growth on 2 blood culture samples after 5 days of incubation. Bacterial pneumonia has been shown to have radiographic clearing after 5 weeks in some patients and in most cases within 2&#x2013;3 months [<xref rid="b27-amjcaserep-17-379" ref-type="bibr">27</xref>].</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>SC inhalation can present as inhalation fever. This case report adds to the growing body of literature on pulmonary sequelae of SC. As the Emergency Department visits by SC abusers are increasing, the importance of physicians being aware of these adverse effects cannot be overstated. Inhalation fever is self-limiting. Treatment is focused on supportive care and causative factor avoidance. Further scientific research is needed to assess the role of endocannabinoid receptors and synthetic cannabinoids in inhalation fever.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn9-amjcaserep-17-379">
        <p>
          <bold>Conflict of interest</bold>
        </p>
        <p>There are no conflicts of interest to be declared by the authors.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References:</title>
      <ref id="b1-amjcaserep-17-379">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elsohly</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gul</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wanas</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Radwan</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Synthetic cannabinoids: analysis and metabolites</article-title>
          <source>Life Sci</source>
          <year>2014</year>
          <volume>97</volume>
          <issue>1</issue>
          <fpage>78</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">24412391</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-amjcaserep-17-379">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pourmand</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mazer-Amirshahi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shokoohi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>The evolving high: new designer drugs of abuse</article-title>
          <source>Hum Exp Toxicol</source>
          <year>2014</year>
          <volume>33</volume>
          <issue>10</issue>
          <fpage>993</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="pmid">24501103</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-amjcaserep-17-379">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zawilska</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>&#x201C;Legal highs&#x201D; &#x2013; an emerging epidemic of novel psychoactive substances</article-title>
          <source>Int Rev Neurobiol</source>
          <year>2015</year>
          <volume>120</volume>
          <fpage>273</fpage>
          <lpage>300</lpage>
          <pub-id pub-id-type="pmid">26070762</pub-id>
        </element-citation>
      </ref>
      <ref id="b4-amjcaserep-17-379">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weaver</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Hopper</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Gunderson</surname>
              <given-names>EW</given-names>
            </name>
          </person-group>
          <article-title>Designer drugs 2015: Assessment and management</article-title>
          <source>Addict Sci Clin Pract</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>8</fpage>
          <pub-id pub-id-type="pmid">25928069</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-amjcaserep-17-379">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carroll</surname>
              <given-names>FI</given-names>
            </name>
            <name>
              <surname>Lewin</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Mascarella</surname>
              <given-names>SW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Designer drugs: A medicinal chemistry perspective</article-title>
          <source>Ann NY Acad Sci</source>
          <year>2012</year>
          <volume>1248</volume>
          <fpage>18</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">22092008</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-amjcaserep-17-379">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Law</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Notes from the field: Increase in reported adverse health effects related to synthetic cannabinoid use &#x2013; United States, January&#x2013;May 2015</article-title>
          <source>MMWR Morb Mortal Wkly Rep</source>
          <year>2015</year>
          <volume>64</volume>
          <issue>22</issue>
          <fpage>618</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="pmid">26068566</pub-id>
        </element-citation>
      </ref>
      <ref id="b7-amjcaserep-17-379">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winstock</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lynskey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Borschmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Waldron</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample</article-title>
          <source>J Psychopharmacol</source>
          <year>2015</year>
          <volume>29</volume>
          <issue>6</issue>
          <fpage>698</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="pmid">25759401</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-amjcaserep-17-379">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hermanns-Clausen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kneisel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Auwarter</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings</article-title>
          <source>Addiction</source>
          <year>2013</year>
          <volume>108</volume>
          <issue>3</issue>
          <fpage>534</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">22971158</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-amjcaserep-17-379">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berkowitz</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Veeraraghavan</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pulmonary effects of synthetic marijuana: Chest radiography and CT findings</article-title>
          <source>Am J Roentgenol</source>
          <year>2015</year>
          <volume>204</volume>
          <issue>4</issue>
          <fpage>750</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">25541904</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-amjcaserep-17-379">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alhadi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tiwari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vohra</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High times, low sats: Diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use</article-title>
          <source>J Med Toxicol</source>
          <year>2013</year>
          <volume>9</volume>
          <issue>2</issue>
          <fpage>199</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="pmid">23539384</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-amjcaserep-17-379">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loschner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cihla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jalali</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ghamande</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Diffuse alveolar hemorrhage: Add &#x201C;greenhouse effect&#x201D; to the growing list</article-title>
          <source>Chest</source>
          <year>2011</year>
          <volume>140</volume>
          <fpage>149A</fpage>
        </element-citation>
      </ref>
      <ref id="b12-amjcaserep-17-379">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Su</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Seely</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Moran</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>2015</year>
          <volume>97</volume>
          <issue>6</issue>
          <fpage>562</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">25788107</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-amjcaserep-17-379">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kersten</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>McLaughlin</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Toxicology and management of novel psychoactive drugs</article-title>
          <source>J Pharm Pract</source>
          <year>2015</year>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>50</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">25261428</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-amjcaserep-17-379">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vemuri</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Makriyannis</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Medicinal chemistry of cannabinoids</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>2015</year>
          <volume>97</volume>
          <issue>6</issue>
          <fpage>553</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="pmid">25801236</pub-id>
        </element-citation>
      </ref>
      <ref id="b15-amjcaserep-17-379">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fantegrossi</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Moran</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Radominska-Pandya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Prather</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: Mechanism underlying greater toxicity?</article-title>
          <source>Life Sci</source>
          <year>2014</year>
          <volume>97</volume>
          <issue>1</issue>
          <fpage>45</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">24084047</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-amjcaserep-17-379">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bronova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Aydogan</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protection from radiation-induced pulmonary fibrosis by peripheral targeting of cannabinoid receptor-1</article-title>
          <source>Am J Respir Cell Mol Biol</source>
          <year>2015</year>
          <volume>53</volume>
          <issue>4</issue>
          <fpage>555</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">26426981</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-amjcaserep-17-379">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morty</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Kuebler</surname>
              <given-names>WM</given-names>
            </name>
          </person-group>
          <article-title>TRPV4: An exciting new target to promote alveolo-capillary barrier function</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2014</year>
          <volume>307</volume>
          <issue>11</issue>
          <fpage>L817</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">25281637</pub-id>
        </element-citation>
      </ref>
      <ref id="b18-amjcaserep-17-379">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balakrishna</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Achanta</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury</article-title>
          <source>Am J Physiol Lung Cell Mol Physiol</source>
          <year>2014</year>
          <volume>307</volume>
          <issue>2</issue>
          <fpage>L158</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">24838754</pub-id>
        </element-citation>
      </ref>
      <ref id="b19-amjcaserep-17-379">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rask-Andersen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pratt</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Inhalation fever: A proposed unifying term for febrile reactions to inhalation of noxious substances</article-title>
          <source>Br J Ind Med</source>
          <year>1992</year>
          <volume>49</volume>
          <issue>1</issue>
          <fpage>40</fpage>
          <pub-id pub-id-type="pmid">1445502</pub-id>
        </element-citation>
      </ref>
      <ref id="b20-amjcaserep-17-379">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>KI</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>MK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Imaging of occupational lung disease</article-title>
          <source>Radiographics</source>
          <year>2001</year>
          <volume>21</volume>
          <issue>6</issue>
          <fpage>1371</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">11706211</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-amjcaserep-17-379">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seifert</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Von Essen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jacobitz</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Organic dust toxic syndrome: A review</article-title>
          <source>J Toxicol Clin Toxicol</source>
          <year>2003</year>
          <volume>41</volume>
          <issue>2</issue>
          <fpage>185</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">12733858</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-amjcaserep-17-379">
        <label>22.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Nemery</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Respiratory diseases caused by acute inhalation of gases, vapours and dusts</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Palange</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Simonds</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <source>ERS Handbook of Respiratory Medicine European Respiratory Society</source>
          <year>2013</year>
          <fpage>273</fpage>
          <lpage>77</lpage>
        </element-citation>
      </ref>
      <ref id="b23-amjcaserep-17-379">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pardo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>TE</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Hypersensitivity pneumonitis: insights in diagnosis and pathobiology</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2012</year>
          <volume>186</volume>
          <issue>4</issue>
          <fpage>314</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">22679012</pub-id>
        </element-citation>
      </ref>
      <ref id="b24-amjcaserep-17-379">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirschmann</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Pipavath</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Godwin</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Hypersensitivity pneumonitis: A historical, clinical, and radiologic review</article-title>
          <source>Radiographics</source>
          <year>2009</year>
          <volume>29</volume>
          <issue>7</issue>
          <fpage>1921</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">19926754</pub-id>
        </element-citation>
      </ref>
      <ref id="b25-amjcaserep-17-379">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akira</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Suganuma</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Acute and subacute chemical-induced lung injuries: HRCT findings</article-title>
          <source>Eur J Radiol</source>
          <year>2014</year>
          <volume>83</volume>
          <issue>8</issue>
          <fpage>1461</fpage>
          <lpage>69</lpage>
          <pub-id pub-id-type="pmid">24853247</pub-id>
        </element-citation>
      </ref>
      <ref id="b26-amjcaserep-17-379">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Megarbane</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chevillard</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>The large spectrum of pulmonary complications following illicit drug use: features and mechanisms</article-title>
          <source>Chem Biol Interact</source>
          <year>2013</year>
          <volume>206</volume>
          <issue>3</issue>
          <fpage>444</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">24144776</pub-id>
        </element-citation>
      </ref>
      <ref id="b27-amjcaserep-17-379">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cassiere</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Niederman</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Community-acquired pneumonia</article-title>
          <source>Dis Mon</source>
          <year>1998</year>
          <volume>44</volume>
          <issue>11</issue>
          <fpage>613</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="pmid">9858958</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-amjcaserep-17-379" position="float">
      <label>Figure 1.</label>
      <caption>
        <p>Chest radiograph on admission that demonstrates diffuse reticulo-nodular and interstitial infiltrates.</p>
      </caption>
      <graphic xlink:href="amjcaserep-17-379-g001"/>
    </fig>
    <fig id="f2-amjcaserep-17-379" position="float">
      <label>Figure 2.</label>
      <caption>
        <p>Chest radiograph 24 hours after admission. PA view shows interval resolution of the reticulo-nodular infiltrates and interstitial infiltrates.</p>
      </caption>
      <graphic xlink:href="amjcaserep-17-379-g002"/>
    </fig>
    <fig id="f3-amjcaserep-17-379" position="float">
      <label>Figure 3.</label>
      <caption>
        <p>Chest Radiograph lateral view at 24hours after admission shows interval resolution of the reticulo-nodular infiltrates and interstitial infiltrates.</p>
      </caption>
      <graphic xlink:href="amjcaserep-17-379-g003"/>
    </fig>
    <table-wrap id="t1-amjcaserep-17-379" position="float">
      <label>Table 1.</label>
      <caption>
        <p>Summary of blood and urine investigations results on admission with the reference ranges.</p>
      </caption>
      <table frame="hsides" rules="rows">
        <thead>
          <tr>
            <th valign="middle" align="center" rowspan="1" colspan="1"/>
            <th valign="middle" align="center" rowspan="1" colspan="1">Result</th>
            <th valign="middle" align="center" rowspan="1" colspan="1">Reference range</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="3" valign="middle" align="left" rowspan="1">CBC</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;White cell count</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">18.5 K/uL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">4.5&#x2013;11.5 K/uL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Hemoglobin</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">13.5 g/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">14&#x2013;18 g/dL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Hematocrit</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">39.4%</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">40&#x2013;54%</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Platelet</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">239 K/uL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">150&#x2013;450 K/uL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Neutrophil</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">15.4 K/uL (83.4%)</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.9&#x2013;7.7 K/uL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Lymphocyte</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.3 K/uL (7.1%)</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">0.7&#x2013;5.0 K/uL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Eosinophil</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">0.1 K/uL (0.5%)</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">0.0&#x2013;0.8 K/uL</td>
          </tr>
          <tr>
            <td colspan="3" valign="middle" align="left" rowspan="1">Chemistry</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum sodium</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">142 mmol/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">136&#x2013;145 mmol/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum potassium</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">3.77 mmol/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">3.5&#x2013;5.1mmol/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum chloride</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">105 mmol/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">98&#x2013;107mmol/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum bicarbonate</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">27 mmol/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">21&#x2013;32 mmol/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Blood urea nitrogen</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">13 mg/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">7&#x2013;18 mg/dL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum creatinine</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.2 mg/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">0.61&#x2013;1.24 mg/dL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum magnesium</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.7 mg/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.8&#x2013;2.4 mg/dL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum phosphorus</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">1.9 mg/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">2.5&#x2013;4.9 mg/dL</td>
          </tr>
          <tr>
            <td colspan="3" valign="middle" align="left" rowspan="1">Hepatic profile</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Aspartate aminotransferase</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">52 U/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">15&#x2013;37 U/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Alanine aminotransferase</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">32 U/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">12&#x2013;78 U/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Alkaline phosphatase</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">93 U/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">50&#x2013;136 U/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Total bilirubin</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">0.7 mg/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">0.2&#x2013;1.0 mg/dL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Total protein</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">6.2 g/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">6.4&#x2013;8.2 g/dL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Albumin</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">3.3 g/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">3.4&#x2013;5.0 g/dL</td>
          </tr>
          <tr>
            <td colspan="3" valign="middle" align="left" rowspan="1">Other tests</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Urine cannabinoid</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;50 ng/mL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Urine opiate</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;300 ng/mL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Urine barbiturate</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;200 ng/mL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Urine cocaine</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;300 ng/mL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Urine benzodiazepine</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;200 ng/mL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Urine methadone</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;300 ng/mL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Urine phencyclidine</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Not available</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Blood alcohol level</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;3.0 mg/dL</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">&lt;5 mg/dL</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Serum creatinine kinase</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">606 U/L</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">39&#x2013;308 U/L</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;HIV-1/HIV-2 Ab</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative for both</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Negative for both</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Blood culture (first sample)</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">No growth after 5 days</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td>
          </tr>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">&#x2003;&#x2003;Blood culture (second sample)</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">No growth after 5 days</td>
            <td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
